Stopping tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia who have achieved deep molecular response could help reduce health expenditure.
Study: TKI Discontinuation Should Be Considered in Patients With CML Achieving Deep Molecular Response
Older age, African American race, and low socioeconomic status may be linked with a reduced likelihood of receiving multiple myeloma treatment of any kind.
For patients with cancer or multiple serious comorbidities, consulting with a palliative care team within 3 days of hospital admission may significantly reduce hospital costs.
A comparative effectiveness study examined clinical outcomes and costs after treatment with a febrile neutropenia therapy vs a biosimilar for patients with non-myeloid cancer undergoing chemotherapy.
Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization.
A recent study analyzed the effects of implementing a clinical pathway for thyroid cancer in a hospital setting.
A JAMA Oncology research letter sheds light on the average additional costs associated with CAR-T therapy, which can be from $30,000 to $36,000 per patient.
A new economic model may help clinicians and payers have a better understanding of the relative clinical benefits and costs of second-line treatment options for metastatic renal cell carcinoma.
A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma.
Real-World Study Determines Effectiveness of Targeted Therapy for Relapsed, Refractory B-Cell Malignancy
A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.